Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Video
Advances in Skin Cancer Diagnosis and Education
Author(s):
In this video interview we sit down with John Dobak, MD, and Laura Ferris, MD, PhD, to talk about DermTech, the TRUST study, and more.
In this exclusive interview with Dermatology Times®, John Dobak, MD, the president and CEO of DermTech, a genomics company in dermatology that’s dedicated to revolutionizing skin cancer detection, discuses the DermTech Melanoma Test and the TRUST study.
Laura Ferris, MD, PhD, a dermatologist and associate professor at the University of Pittsburgh Clinical and Translational Science Institute Director of Clinical Trials, UPMC Department of Dermatology, also talked about how to evaluate patient risk factors, patient education, and how Covid-19 has affected melanoma detection.
Related Videos
Related Content
